Introduction And Epidemiology
- Constitutes most common childhood malignancy.
- Accounts for 75-80% of all pediatric leukemias.
- Peak incidence occurs between 2-5 years of age.
- Arises from clonal proliferation of lymphoid precursors (B-cell or T-cell lineage).
- Increased risk associated with
- Down syndrome (15-20 fold increased risk)
- Neurofibromatosis
- Schwachman-Diamond syndrome
- Bloom syndrome
- Ataxia telangiectasia.
Clinical Manifestations
| Category | Clinical Manifestations | Pathophysiology/Notes |
|---|---|---|
| Bone Marrow Replacement | Pallor, fatigue, lethargy, petechiae, purpura, mucosal bleeding, fever, severe infections | Anemia, thrombocytopenia, and neutropenia due to healthy cell displacement. |
| Extramedullary Infiltration | Lymphadenopathy, hepatomegaly, splenomegaly | Present in >60% of cases. |
| Musculoskeletal | Bone/joint pain, tenderness, limp | Secondary to periosteal leukemic involvement. |
| Central Nervous System | Headache, emesis, cranial nerve palsies (commonly VI), papilledema, altered sensorium | Leukemic involvement of the CNS. |
| Genitourinary | Painless testicular enlargement | Can be unilateral or bilateral. |
| Thoracic | Mediastinal mass, superior vena cava syndrome, wheezing, respiratory distress, stridor | Predominantly associated with T-cell lineage. |
Diagnostic Evaluation
| Diagnostic Modality | Focus / Findings |
|---|---|
| Complete Blood Count (CBC) | Assesses leukocyte count (leukopenia to hyperleukocytosis >100,000/mm³). Anemia and thrombocytopenia are typically profound. |
| Peripheral Smear | Demonstrates the presence of circulating lymphoblasts. |
| Bone Marrow Aspiration/Biopsy | Definitive diagnostic test; requires >20% (WHO criteria) or >25% blasts. |
| Cerebrospinal Fluid (CSF) Analysis | Cytology required to exclude CNS involvement. First intrathecal chemotherapy dose is administered during this tap. |
| Metabolic Screening | Evaluates Uric acid, potassium, phosphorus, calcium, LDH, and renal/hepatic function to assess for Tumor Lysis Syndrome. |
| Cytochemistry | Confirms lineage; specifically Myeloperoxidase negative and Terminal deoxynucleotidyl transferase (TdT) positive. |
| Immunophenotyping (Flow Cytometry) | Identifies lineage. B-cell markers: CD10, CD19, CD20, CD22. T-cell markers: CD2, CD3, CD4, CD5, CD7, CD8. |
| Cytogenetics / Molecular | Utilizes Karyotyping, FISH, and PCR to detect critical translocations and prognostic genetic abnormalities. |
Genetics And Risk Stratification
Cytogenetic Abnormalities And Prognostic Implications
| Genetic Abnormality / Translocation | Affected Gene | Frequency (%) | Prognostic Implication |
|---|---|---|---|
| Hyperdiploidy (>50 chromosomes) | Multiple | 20-30 | Excellent prognosis. |
| t(12;21)(p13;q22) | ETV6-RUNX1 | 15-25 | Excellent prognosis; minimal therapy required. |
| Trisomy 4 and 10 | Multiple | 20-25 | Excellent prognosis. |
| t(9;22)(q34;q11.2) | BCR-ABL1 (Philadelphia) | 2-4 | Very high risk; improved outcome with tyrosine kinase inhibitors. |
| t(4;11)(q21;q23) | MLL-AF4 (KMT2A) | 1-2 | Infant ALL; extremely poor prognosis. |
| Hypodiploidy (<44 chromosomes) | Multiple | 1-2 | Unsatisfactory outcome. |
| iAMP21 | Intrachromosomal amplification 21 | 1 | Adverse factor. |
National Cancer Institute (NCI) Classification
Serves as primary clinical baseline for initial risk assignment.
- Standard Risk (SR): Age 1 to 10 years AND white blood cell (WBC) count <50,000/μL.
- High Risk (HR): Age 10 years OR initial WBC count 50,000/μL.
Minimal Residual Disease (MRD)
Single most powerful prognostic indicator.
- Measurement: Flow cytometry, polymerase chain reaction, or next-generation sequencing.
- Favorable Threshold: Day 29 bone marrow MRD <0.01%.
- Adverse Threshold: Persistence of MRD 0.01% at end of induction; mandates treatment intensification.
Prognostic Factors Profile
| Factor | Favorable Profile | Adverse Profile |
|---|---|---|
| Age | 1 to 10 years | <1 year (infant) or 10 years |
| Initial WBC Count | <50,000/μL | 50,000/μL |
| Immunophenotype | B-precursor cell | T-cell (historically), Mature B-cell |
| Extramedullary Disease | Absent | Central nervous system (CNS3) or testicular involvement |
| Cytogenetics (Ploidy) | Hyperdiploidy (>50 chromosomes), DNA index >1.16 | Hypodiploidy (<44 chromosomes), DNA index <0.81 |
| Translocations | t(12;21) / ETV6-RUNX1, Trisomies 4 and 10 | t(9;22) / BCR-ABL1 (Philadelphia), KMT2A (MLL) rearrangement, iAMP21, Ph-like |
Advanced Risk Grouping
B-Cell Lineage
Incorporates NCI criteria, cytogenetics, and MRD.
- Low Risk: SR criteria, favorable cytogenetics, MRD <0.01%.
- Standard Risk: Sub-stratified into Favorable, Average, and High based on cytogenetics, CNS status, and day 29 MRD.
- High Risk: HR criteria or SR with adverse features (steroid pretreatment, specific cytogenetics).
- Very High Risk: End of consolidation MRD 0.01%.
T-Cell Lineage
Stratification distinct from B-ALL; heavily dependent on MRD response.
- Standard Risk: Day 29 marrow MRD <0.01%, no CNS/testicular disease.
- Intermediate Risk: Day 29 marrow MRD 0.01%, but end of consolidation MRD <0.1%.
- Very High Risk: End of consolidation MRD 0.1% or induction failure.
Management And Treatment Strategies
The management of Acute Lymphoblastic Leukemia (ALL) is a complex, risk-adapted process involving systemic chemotherapy, CNS-directed therapy, and supportive care. Below is the summary of strategies based on the current clinical protocols.
Management Strategies for ALL
| Phase | Primary Objective | Treatment Details and Agents |
|---|---|---|
| Induction | Eradicate leukemia from bone marrow (<5% blasts). |
|
| CNS Preventive | Treat subclinical CNS disease; bypass blood-brain barrier. |
|
| Intensification (Consolidation) | Tackle drug resistance post-remission. |
|
| Interim Maintenance | Maintain remission during marrow recovery. |
|
| Delayed Intensification | Eliminate residual resistant clones (re-induction/re-consolidation). |
|
| Maintenance | Eradicate minimal residual disease (MRD) over 2-3 years. |
|
General Supportive Care
- Tumor Lysis Syndrome (TLS) Prevention: Aggressive intravenous hydration (2-3 times maintenance). Administer Allopurinol (300 mg/m²/day) or Rasburicase (0.15-0.2 mg/kg/day IV) for high-risk patients (WBC >100,000/mm³). Monitor electrolytes meticulously.
- Infection Prophylaxis: Pneumocystis jirovecii prophylaxis (Trimethoprim-sulfamethoxazole) mandatory throughout therapy.
- Febrile Neutropenia Management: Prompt hospitalization. Immediate broad-spectrum intravenous antibiotics (covering pseudomonas). Add antifungals if fever persists beyond 3-5 days.
- Transfusion Support: Irradiated, leukoreduced, cytomegalovirus-safe packed red blood cells and platelets administered for severe anemia or thrombocytopenia.
Phases Of Systemic Chemotherapy
1. Remission Induction Therapy
- Objective: Eradicate leukemia from bone marrow, restoring normal hematopoiesis (<5% blasts, normal counts).
- Duration: 4 weeks.
- Efficacy: Induces remission in 95-98% of patients.
- Standard Risk Regimen (3-Drug):
- Glucocorticoid: Dexamethasone (6 mg/m²/day PO) or Prednisone. Dexamethasone improves CNS penetration and event-free survival but increases osteonecrosis risk in older children.
- Vincristine: 1.5 mg/m² IV weekly (Days 0, 7, 14, 21).
- L-Asparaginase: Pegylated asparaginase (PEG-asp) 2500 units/m² IV (Day 4).
- High Risk Regimen (4-Drug):
- Adds Anthracycline: Daunorubicin (25-30 mg/m² IV weekly) to the 3-drug backbone.
- CNS Therapy: Age-adjusted Intrathecal (IT) Methotrexate and/or Cytarabine administered on Day 1, 8, and 29.
2. Consolidation Therapy (CNS Preventive Therapy)
- Objective: Eradicate subclinical disease in sanctuary sites (CNS and testes) and prevent drug resistance.
- Duration: 4 to 8 weeks.
- Regimen (Standard Risk):
- 6-Mercaptopurine (6-MP): 75 mg/m²/day PO for 28 days.
- Vincristine: 1.5 mg/m² IV on Day 1.
- Intrathecal Methotrexate: Administered on Days 1, 8, 15.
- High-Risk / T-cell Modifications: Utilizes intensive systemic therapy including high-dose Cytarabine, Cyclophosphamide, and PEG-asparaginase.
- Cranial Radiation Therapy (CRT): Eliminated for most patients to prevent neurocognitive late effects. Strictly reserved for patients with overt CNS3 disease at diagnosis (1800 cGy administered during later phases).
3. Interim Maintenance
- Objective: Maintain remission while allowing marrow recovery prior to delayed intensification.
- Duration: 8 weeks.
- Regimen Options:
- Capizzi Methotrexate (CMTX): Escalating intravenous Methotrexate doses starting at 100 mg/m² without Leucovorin rescue. Improves survival in Standard Risk patients.
- High-Dose Methotrexate (HDMTX): 5000 mg/m² IV over 24 hours followed by Leucovorin rescue. Significantly improves outcomes for High-Risk patients.
- Concurrent Medications: Vincristine pulses, IT Methotrexate.
4. Delayed Intensification
- Objective: Re-induction and re-consolidation to eliminate residual resistant leukemic clones. Crucial for preventing late relapse.
- Duration: 8 weeks.
- Regimen Details:
- Part 1 (Re-induction): Dexamethasone (10 mg/m²/day), Vincristine (1.5 mg/m² IV weekly), Doxorubicin (25 mg/m² IV weekly), PEG-asparaginase (2500 units/m² IV).
- Part 2 (Re-consolidation): Cyclophosphamide (1000 mg/m² IV), Cytarabine (75 mg/m²/day IV), 6-Thioguanine (60 mg/m²/day PO).
- CNS Therapy: IT Methotrexate.
5. Maintenance (Continuation) Therapy
- Objective: Eradicate minimal residual cell burden (10⁹-10¹⁰ cells) to prevent relapse.
- Duration: Prolonged phase lasting up to 2-3 years from diagnosis.
- Standard Backbone:
- 6-Mercaptopurine: 75 mg/m²/day PO administered continuously. Thiopurine methyltransferase (TPMT) genotyping required to adjust dosage and prevent profound myelosuppression.
- Methotrexate: 20 mg/m²/dose PO administered weekly.
- Pulses: Dexamethasone (3 mg/m²/dose BID for 5 days) and Vincristine (1.5 mg/m² IV) administered every 4 to 12 weeks depending on specific protocol.
- CNS Therapy: IT Methotrexate every 12 weeks.
- Monitoring: Titrate 6-MP and MTX to maintain absolute neutrophil count between 1500-2000/μL.
Management Of Specific ALL Subtypes
Philadelphia Chromosome-Positive (Ph+) ALL
- Features t(9;22) BCR-ABL1 translocation; historically carried grave prognosis.
- Targeted Therapy: Tyrosine Kinase Inhibitors (TKI) seamlessly integrated into standard chemotherapy backbones.
- Agents: Imatinib or Dasatinib administered continuously.
- Outcomes: TKI integration has dramatically improved 3-year survival to 80%. Routine Hematopoietic Stem Cell Transplant (HSCT) in first remission no longer universally required unless response to TKI is poor.
Infant ALL
- Age <1 year; highly associated with KMT2A (MLL) translocations.
- Extremely aggressive biological behavior.
- Therapy: Exceedingly intensive regimens utilizing high-dose Cytarabine and high-dose Methotrexate.
- Transplantation: High-risk infants frequently require allogeneic HSCT in first remission.
Mature B-Cell ALL (Burkitt Leukemia)
- Biologically identical to Burkitt Lymphoma; features FAB L3 morphology.
- Therapy Paradigm: Short, highly intensive pulsed chemotherapy (e.g., FAB/LMB 96 protocol).
- Agents: High-dose Cyclophosphamide, Methotrexate, Cytarabine.
- Immunotherapy: Rituximab (anti-CD20 monoclonal antibody) drastically improves survival (90-95% EFS).
- Maintenance therapy is entirely omitted for mature B-cell ALL.
T-Cell ALL
- High risk for CNS relapse and induction failure.
- Therapy: Utilizes intensified consolidation featuring Nelarabine (T-cell specific purine nucleoside analog) (650 mg/m² IV for 5 days) and high-dose Cytarabine/Methotrexate.
- Prophylactic cranial radiation historically utilized, but modern intensive systemic/intrathecal therapies increasingly negate its requirement.
Management Of Relapsed And Refractory Disease
- 15-20% of patients experience relapse (bone marrow, CNS, or testes).
- Re-induction Protocols: UK ALL R3 or COG platforms utilize intensive combinations.
- Example Regimen (Triple Reinduction): Vincristine, Prednisone, PEG-asparaginase, Doxorubicin, Cyclophosphamide, Etoposide, Cytarabine.
- Prognosis: Determined by time to relapse (early vs. late) and site (medullary vs. extramedullary). Early bone marrow relapses carry dismal prognoses, requiring prompt HSCT.
Novel Targeted And Cellular Therapies (Refractory/Relapsed Settings) recent
Revolutionizing salvage therapy for relapsed/refractory B-ALL.
- Blinatumomab: Bispecific T-cell engager (BiTE). Dual affinity for CD19 (on leukemic blasts) and CD3 (on cytotoxic T-cells), activating endogenous T-cells to lyse blasts.
- Inotuzumab Ozogamicin: Antibody-drug conjugate targeting CD22, delivering cytotoxic calicheamicin directly into blasts.
- Chimeric Antigen Receptor (CAR) T-Cell Therapy (Tisagenlecleucel):
- Autologous T-cells genetically engineered ex vivo to express receptors targeting CD19 antigen.
- Elicits profound, durable remissions in highly refractory patients.
- Complication Management: High risk for Cytokine Release Syndrome (CRS). Requires meticulous monitoring; managed with Tocilizumab (Anti-IL-6 receptor antibody) and Corticosteroids.
Hematopoietic Stem Cell Transplantation (HSCT)
- Reserved for specific high-risk indications due to significant morbidity and mortality (graft-versus-host disease, severe infections, late effects).
- Absolute Indications (ALL):
- Primary induction failure (failure to achieve remission by end of induction).
- Early bone marrow relapse (<18-36 months from diagnosis).
- Second or subsequent remissions.
- Specific cytogenetic abnormalities failing initial targeted therapy (e.g., refractory Ph+ ALL, extremely poor-responding MLL-rearranged infant ALL, extreme hypodiploidy).
- Preparative Conditioning: Typically utilizes Total Body Irradiation (TBI) (1200-1350 cGy) paired with high-dose Cyclophosphamide or Etoposide to ablate marrow and provide immunosuppression.